3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension

Delivery Timing and Midwifery Management

Delivery is the definitive cure for preeclampsia, as the placenta is the fundamental source of the circulating antiangiogenic factors (e.g., soluble fms-like tyrosine kinase-1 [sFlt-1] and soluble endoglin) driving widespread maternal endothelial injury. However, delivery timing requires balancing maternal stabilization against the risks of neonatal prematurity.

Delivery Timing Guidelines (ACOG/SMFM Standards)

• Gestational Hypertension and Preeclampsia without Severe Features:
  • Timing: Deliver at 37 0/7 weeks gestation (or upon diagnosis if diagnosed at ≥37 weeks).
  • Evidence: Expectant management beyond 37 weeks increases the risk of severe preeclampsia, abruption, and cesarean birth without neonatal benefit.
• Preeclampsia with Severe Features:
  • Timing at ≥34 0/7 weeks: Delivery is indicated upon stabilization.
  • Timing <34 0/7 weeks (Expectant Inpatient Management): In carefully selected, stable patients admitted to a tertiary perinatal center with Level III/IV NICU care, expectant management up to 34 0/7 weeks may be pursued to allow administration of antenatal corticosteroids (betamethasone 12 mg IM q24h x 2 doses) for fetal lung maturity.
  • Absolute Indications for Immediate Delivery at Any Gestational Age:
    • Uncontrolled severe-range hypertension refractory to dual-agent pharmacotherapy
    • Eclampsia
    • Pulmonary edema
    • Placental abruption
    • Disseminated intravascular coagulation (DIC)
    • Progressive renal failure (doubling of creatinine or acute anuria)
    • Persistent, severe epigastric/RUQ pain with hepatic rupture or subcapsular hematoma
    • Non-reassuring fetal status (Category III FHR tracing or persistent biophysical profile ≤4/10)
• Mode of Delivery: Induction of labor for vaginal birth is preferred unless standard obstetric indications for cesarean delivery exist. Cervical ripening (e.g., mechanical with Foley balloon or pharmacologic) should be initiated when the cervix is unfavorable. Cesarean delivery is reserved for fetal distress, failed induction, malpresentation, or catastrophic maternal collapse.

Primary Prevention: Low-Dose Aspirin Prophylaxis

Low-dose aspirin inhibits platelet cyclooxygenase-1 (COX-1), shifting the balance of vasoactive prostanoids away from vasoconstrictive thromboxane A2 and toward vasodilatory prostacyclin (PGI2), thereby improving spiral artery remodeling and placental perfusion.

• Target Population:
  • High-Risk (Recommend Aspirin if ≥1 High-Risk Factor Present):
    • History of preeclampsia, especially early-onset or complicated by adverse outcomes
    • Multifetal gestation
    • Chronic hypertension
    • Pregestational diabetes mellitus (Type 1 or Type 2)
    • Pre-existing renal disease
    • Autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome)
  • Moderate-Risk (Consider Aspirin if ≥2 Moderate-Risk Factors Present):
    • Nulliparity
    • Obesity (pre-pregnancy BMI ≥30 kg/m²)
    • Family history of preeclampsia (mother or sister)
    • Advanced maternal age (≥35 years)
    • Sociodemographic characteristics (e.g., lower socioeconomic status, Black race due to systemic healthcare inequities)
    • Interpregnancy interval >10 years
    • Personal history of small-for-gestational-age infant or prior adverse pregnancy outcome
• Dosage and Timing:
  • Dose: 81 to 162 mg daily (many clinical centers now utilize 162 mg [two 81 mg tablets] daily for higher efficacy).
  • Initiation: Between 12 and 16 weeks gestation (optimally before 16 weeks; acceptable up to 28 weeks).
  • Duration: Continued daily until delivery (or discontinued at 36–37 weeks per local clinical protocol).

Postpartum Blood Pressure Surveillance and Long-Term Risk

Delivery removes the placenta, but it does not immediately remove the disease. Blood pressure in hypertensive disorders of pregnancy typically peaks on postpartum days 3 through 6 as extravascular fluid mobilizes back into the intravascular space — after most patients have already gone home.

Surveillance Standards

• De novo postpartum preeclampsia and eclampsia can present for the first time up to 6 weeks after birth. Any postpartum patient with a new severe headache, visual change, epigastric pain, or dyspnea needs a blood pressure and a preeclampsia panel, not reassurance.
• ACOG recommends a blood pressure evaluation no later than 7 to 10 days postpartum for all hypertensive disorders of pregnancy, and within 72 hours for patients who had severe-range readings. Home blood pressure monitoring with text-based or remote reporting improves follow-up and has been shown to narrow racial disparities in postpartum readmission.
• Give every hypertensive patient written return precautions before discharge, naming the specific symptoms and the phone number to call.

Postpartum Pharmacologic Management

• Treat severe-range postpartum blood pressure with the same first-line agents used antepartum: IV labetalol, IV hydralazine, or oral immediate-release nifedipine.
• For maintenance, extended-release nifedipine and labetalol are both effective and lactation-compatible. Methyldopa is generally avoided postpartum because of its association with depression.
• NSAIDs are appropriate postpartum analgesia even in hypertensive patients and are preferred over opioids; current ACOG guidance does not support withholding them on the basis of hypertension alone.
• Continue magnesium sulfate for at least 24 hours postpartum in preeclampsia with severe features, eclampsia, and HELLP syndrome.

Lifelong Cardiovascular Implications

A hypertensive disorder of pregnancy is a sex-specific cardiovascular risk factor, not a self-limited obstetric event.

• Compared with normotensive pregnancy, a history of preeclampsia confers roughly twice the lifetime risk of ischemic heart disease and stroke and about four times the risk of heart failure.
• The ACC/AHA and ACOG recommend that the adverse pregnancy outcome be documented in the permanent problem list and communicated to the primary care clinician, with ongoing blood pressure, lipid, and glucose screening.
• Counsel about interpregnancy care: weight and blood pressure optimization, and low-dose aspirin from 12 to 16 weeks in the next pregnancy, since prior preeclampsia is a high-risk indication on its own.